G. David Roodman, MD, PhD
Vice Chair for Research
Department of Medicine
Director, Myeloma Program, Bone Biology Center
University of Pittsburgh Medical Center
Dr. David Roodman received his medical degree from the University of Kentucky College of Medicine and a doctorate in biochemistry from the University of Kentucky. His postdoctoral training included an internship in internal medicine at the University of Kentucky, as well as a residency in medicine and a hematology fellowship at the University of Minnesota. Dr. Roodman currently serves as director of the myeloma program at the University of Pittsburgh Cancer Institute and vice chair for research in the University of Pittsburgh School of Medicine’s Department of Medicine.
Dr. Roodman holds membership in numerous professional societies such as the American Board of Internal Medicine, diplomate in internal medicine and hematology, and a diplomate of the National Board of Medical Examiners. Dr. Roodman also holds positions of prominence with several advisory and regulatory bodies, including chair of the Paget Foundation. He is well-published in peer-reviewed literature and is on the editorial boards of several journals, including Experimental Biology and Medicine, Journal of Clinical Investigation, and Experimental Hematology.
Dr. Roodman has been in the forefront of research to understand the role of the marrow microenvironment in promoting hematologic malignancies. His research spans studies of both normal and pathologic conditions associated with increased osteoclast and osteoblast activity, and he is a highly sought lecturer on these topics.
Dr. David Roodman has received consulting fees from Amgen Inc. and Millennium Pharmaceuticals, Inc.